Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Panel Embraces Sanofi Diabetes Combo, Shuns 'Pen' Devices

Executive Summary

While the FDA's Endocrinologic and Metabolic Drugs Advisory Committee backed approval of Sanofi SA's fixed-ratio combination type 2 diabetes medicine, many of the panelists objected to the two complicated pen devices the company is proposing to use to administer the drug – calling for them to be redesigned.


Related Content

Panel Back's Novo's Diabetes Combo, But Will The Market?
Sanofi's 2-Pen Diabetes Combo Perplexes FDA
FDA On Novo's Diabetes Combo: It's Complicated
Lantus Follow-On Basaglar OK'd, But Can Lilly Sell It?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts